{"nctId":"NCT00000136","briefTitle":"Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)","startDateStruct":{"date":"1990-03"},"conditions":["HIV Infections","Cytomegalovirus Retinitis"],"count":234,"armGroups":[{"label":"Foscarnet","type":"EXPERIMENTAL","interventionNames":["Drug: Foscarnet","Drug: Ganciclovir"]},{"label":"Ganciclovir","type":"EXPERIMENTAL","interventionNames":["Drug: Foscarnet","Drug: Ganciclovir"]}],"interventions":[{"name":"Foscarnet","otherNames":["Foscavir"]},{"name":"Ganciclovir","otherNames":["Vitraset"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* CMV retinitis in one or both eyes\n* At least 1/4 disk are of one CMV lesion photographable\n* Diagnosis of AIDS as defined by Center for Disease Control criteria or documented HIV infection\n* Age 13 and greater\n* Visual acuity ≥ 3/200 in at least one eye diagnosed with CMV retinitis\n* Absolute neutrophil count ≥ 1,000 cells/µl\n* Platelet ≥ 25,000 cells/µl\n* Serum creatinine ≥ 2.0 mg/dl\n* Karnofsky score ≥ 60\n* Informed consent\n\nExclusion criteria:\n\n* Previous treatment of CMV retinitis\n* Treatment with anti-CMV therapy for an extra-ocular CMV infection currently or in the past 28 days\n* Known or suspected allergy to study drugs\n* Pregnant or Lactating","healthyVolunteers":false,"sex":"ALL","minimumAge":"13 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mortality","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"127","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":60,"n":107},"commonTop":[]}}}